Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13360497 | 0.80 | — | — | |
| SCHEMBL1106716 | 0.77 | — | — | |
| SCHEMBL14815 | 0.76 | GABRA1 (0.37) | — | |
| SCHEMBL826704 | 0.74 | GABRA1 (0.35) | — | |
| SCHEMBL14999211 | 0.68 | GABRA1 (0.32) | — | |
| SCHEMBL7216843 | 0.67 | — | — | |
| SCHEMBL7216842 | 0.67 | — | — | |
| SCHEMBL31464904 | 0.65 | NQO1 (0.34) | — | |
| SCHEMBL426079 | 0.64 | — | — | |
| SCHEMBL22984406 | 0.64 | TRPA1 (0.35) | GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12036319-B2 | Polyvalent sting activating compositions and uses thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240067626-A1 | INHIBITORS OF MET KINASE | CELYN THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230374022-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230365552-A1 | LYSERGIC ACID DERIVATIVES AND METHODS | The Florida State University Research Foundation, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | BCP3 PTY LIMITED (AU) | 2023-11-09 | — | — | US | disclosed |
| US-11807701-B2 | Biofouling resistant coatings and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20130029948-A1 | HETEROCYCLIC AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120196839-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110319445-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110269743-A1 | PHENYLTHIOPHENYLDIHYDROBENZOTHIAZEPINE INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CalciMedica, Inc (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110257177-A1 | BENZYLTHIOTETRAZOLE INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20100305200-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2010-12-02 | — | — | US | disclosed |
| US-20090253745-A1 | MODULATORS OF OCULAR OXIDATIVE STRESS | SIRION THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | GPR55 2663/4885 |
| US-20230374022-A1 | INHIBITORS OF PARG | PARG, PLG, SERPINB1 | GPR55 2281/4885 |
| US-20120196839-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | GPR55 67/4885 |
| US-20130040983-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | GPR55 4107/4885 |
| US-20090253745-A1 | MODULATORS OF OCULAR OXIDATIVE STRESS | GPX4, GPX1, ALDH1A2 | GPR55 2275/4885 |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | GPR55 2616/4885 |
| US-12036319-B2 | Polyvalent sting activating compositions and uses thereof | STING1, CGAS, TLR7 | GPR55 750/4885 |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | GPR55 40/4885 |
| US-20130029948-A1 | HETEROCYCLIC AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, UACA | GPR55 4005/4885 |
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | TYK2, JAK2, PTK2B | GPR55 3050/4885 |
| US-20110319445-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | GPR55 48/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | GPR55 4470/4885 |
| US-20100305200-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, ATP2A1 | GPR55 1030/4885 |
| US-20110269743-A1 | PHENYLTHIOPHENYLDIHYDROBENZOTHIAZEPINE INHIBITORS OF STORE OPERATED CALCIUM RELEASE | SARAF, ORAI1, RYR2 | GPR55 1508/4885 |
| US-20240067626-A1 | INHIBITORS OF MET KINASE | MET, RET, MERTK | GPR55 1970/4885 |
| US-20110257177-A1 | BENZYLTHIOTETRAZOLE INHIBITORS OF STORE OPERATED CALCIUM RELEASE | SARAF, CACNA1I, ORAI1 | GPR55 1599/4885 |
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MUC1, MPO, SERPINB1 | GPR55 2048/4885 |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | GPR55 988/4885 |
| US-20230365552-A1 | LYSERGIC ACID DERIVATIVES AND METHODS | AADAT, HTR3A, HNMT | GPR55 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.